Form 4: Denali Therapeutics CEO Ryan Watts Executes Pre-Planned Stock Option Exercises and Sales

Denali Therapeutics Inc.'s President and CEO, Ryan J. Watts, reported the exercise of stock options and subsequent sale of common stock totaling 495,282 shares, primarily under a Rule 10b5-1 trading plan.

Summary

• Ryan J. Watts, President and CEO, and a Director of Denali Therapeutics Inc. (DNLI), reported transactions on July 9, 2025.
• Watts exercised options to acquire 455,282 shares of common stock at an exercise price of $0.68 per share.
• Watts also exercised options to acquire an additional 40,000 shares of common stock at an exercise price of $5.28 per share.
• Following these exercises, Watts sold 495,282 shares of common stock at a weighted average sale price ranging from $15.00 to $15.08 per share.
• The sales were conducted pursuant to a Rule 10b5-1 selling plan established on September 16, 2024.
• After the reported transactions, Ryan Watts directly holds 253,071 shares of common stock, which includes 177,940 unvested Restricted Stock Units (RSUs).
• Additionally, 2,202,604 shares are indirectly held by the Watts Family 2015 Trust, for which Ryan Watts serves as trustee.
• One stock option for 455,282 shares, exercised in this report, has 50% of its shares contingent on the Issuer's common stock reaching or exceeding $80.00 per share on NASDAQ for 90 consecutive trading days.
• Another stock option for 40,000 shares, also exercised, had 25% vest on March 8, 2018, with an additional 1/48 of shares vesting monthly thereafter.

Sentiment

Score: 7

Explanation: The sentiment is generally positive for the insider due to profitable transactions. For the company, it's neutral to slightly positive as the sales were pre-planned via a 10b5-1 plan, and a performance-based vesting condition points to a high future stock price target.

Positives

• The sale of shares at a weighted average price of $15.00 to $15.08, significantly higher than the exercise prices of $0.68 and $5.28, indicates a profitable transaction for the insider.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, established on September 16, 2024, suggesting a planned liquidity event rather than a reaction to new company-specific negative news.
• A significant portion of the exercised options (455,282 shares) had a performance-based vesting condition tied to the company's stock price reaching $80.00 for 90 consecutive trading days, indicating a long-term growth target for the company.

Future Outlook

A portion of the exercised stock options (455,282 shares) had a performance-based vesting condition, with 50% of the shares vesting if Denali Therapeutics' common stock reaches or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days, indicating a significant future stock price target.

Management Comments

• The sales reported were made pursuant to a previously signed/adopted Rule 10b5-1 Selling plan dated September 16, 2024.
• The shares sold primarily relate to 455,282 stock options that expire on August 21, 2025.
• The Reporting Person serves as trustee for the Watts Family 2015 Trust, which holds a significant portion of the indirectly owned shares.

Industry Context

This Form 4 filing details routine insider transactions (option exercises and sales) and does not provide broader industry trends or competitive insights. Such filings are standard disclosures for executive compensation and liquidity events.

Related Party Transactions

• 2,202,604 shares are held indirectly by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person, Ryan J. Watts, serves as trustee.

Stakeholder Impact

• Shareholders are informed of the CEO's stock option exercises and sales, which were pre-planned and profitable, potentially signaling confidence in the company's long-term value given the performance-based vesting conditions for some options.
• The transactions provide liquidity for the CEO, which is a common aspect of executive compensation.

Next Steps

• The remaining 50% of shares from a specific stock option will vest upon the achievement of the Issuer's common stock reaching or exceeding $80.00 per share on NASDAQ for 90 consecutive trading days.

Key Dates

Recommendation

Keywords

Denali Therapeutics, DNLI, Form 4, Insider Trading, Stock Options, CEO, Director, Stock Sale, Rule 10b5-1, Equity Compensation